Introduction: 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is a potential imaging agent of hypoxic tumor for use with PET. Recent literature indicates that cancer cells expressing CD133, which is a frequently used marker for so-called cancer stem cells or cancer stem cell-like cells (collectively referred here as CSC\u27s), contribute to tumor\u27s therapeutic resistance and metastasis ability and possess hypoxia resistance. Here, we investigated relationships between 64Cu-ATSM accumulation and existence of CD133+ cells using mouse colon carcinoma (Colon-26) tumor. Methods: Intratumor distribution of 64Cu-ATSM and 18F-fluorodeoxyglucose (18FDG) was compared with immunohistochemical staining for CD133 with a Colon-26 model. In...
The cancer stem cell model suggests that only a rare subpopulation, known as cancer stem cells (CSC)...
SummaryA novel paradigm in tumor biology suggests that cancer growth is driven by stem-like cells wi...
INTRODUCTION: Recent evidence based on cancer stem cell (CSC) models, is boosting the progress of tr...
ntroduction: Cancer stem cells are recently noticed to contribute to tumor malignant behaviors, such...
ntroduction: Cancer stem cells are recently noticed to contribute to tumor malignant behaviors, such...
Objectives: 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is a PET imaging agent target...
Introduction64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is an imaging agent for posit...
64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is a promising theranostic agent targetin...
The purpose of this study is to reveal characteristics of 64Cu-labeled diacetyl-bis(N4-methylthiosem...
(64)Cu-diacetyl-bis (N(4)-methylthiosemicarbazone) ((64)Cu-ATSM) is a potential theranostic agent ta...
Intratumoral distribution of [Cu-64]Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) and flu...
Cu-ATSM, a hypoxia imaging agent, effectively detects tumors due to the presence of hypoxia in solid...
According to the cancer stem cell (CSC) model, higher CD133 expression in tumor tissue is associated...
<div><p>According to the cancer stem cell (CSC) model, higher CD133 expression in tumor tissue is as...
Emerging evidence suggests that tumors contain and are driven by a cellular component that displays ...
The cancer stem cell model suggests that only a rare subpopulation, known as cancer stem cells (CSC)...
SummaryA novel paradigm in tumor biology suggests that cancer growth is driven by stem-like cells wi...
INTRODUCTION: Recent evidence based on cancer stem cell (CSC) models, is boosting the progress of tr...
ntroduction: Cancer stem cells are recently noticed to contribute to tumor malignant behaviors, such...
ntroduction: Cancer stem cells are recently noticed to contribute to tumor malignant behaviors, such...
Objectives: 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is a PET imaging agent target...
Introduction64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is an imaging agent for posit...
64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is a promising theranostic agent targetin...
The purpose of this study is to reveal characteristics of 64Cu-labeled diacetyl-bis(N4-methylthiosem...
(64)Cu-diacetyl-bis (N(4)-methylthiosemicarbazone) ((64)Cu-ATSM) is a potential theranostic agent ta...
Intratumoral distribution of [Cu-64]Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) and flu...
Cu-ATSM, a hypoxia imaging agent, effectively detects tumors due to the presence of hypoxia in solid...
According to the cancer stem cell (CSC) model, higher CD133 expression in tumor tissue is associated...
<div><p>According to the cancer stem cell (CSC) model, higher CD133 expression in tumor tissue is as...
Emerging evidence suggests that tumors contain and are driven by a cellular component that displays ...
The cancer stem cell model suggests that only a rare subpopulation, known as cancer stem cells (CSC)...
SummaryA novel paradigm in tumor biology suggests that cancer growth is driven by stem-like cells wi...
INTRODUCTION: Recent evidence based on cancer stem cell (CSC) models, is boosting the progress of tr...